Fractyl Health, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GUTS Nasdaq 2836 fractyl.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fractyl Health, Inc.

Fractyl Health to Participate in Upcoming September Investor Conferences - Sep 9th, 2026 5:00 am
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance - Sep 1st, 2026 3:01 pm
Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day - Sep 1st, 2026 6:56 am
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance - Aug 20th, 2026 5:00 am
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial - Aug 14th, 2026 3:04 am
Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary - Aug 11th, 2026 7:50 pm
Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ... - Aug 10th, 2026 11:03 pm
Fractyl Health Q2 Earnings Call Highlights - Aug 10th, 2026 5:04 pm
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates - Aug 10th, 2026 2:05 pm
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 - Aug 3rd, 2026 2:05 pm
Fractyl Health to Participate in Upcoming Investor Events - Jul 22nd, 2026 2:01 pm
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results - Jul 16th, 2026 8:13 am
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s - Jul 15th, 2026 7:02 am
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation - Jul 15th, 2026 4:00 am
Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity - Jul 11th, 2026 3:09 pm
Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding - Jun 11th, 2026 9:23 pm
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure - Jun 4th, 2026 5:00 am
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy - Jun 1st, 2026 5:00 am
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround - May 16th, 2026 2:13 pm
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income - May 14th, 2026 7:19 am